ArticleBMC cancer2026
Efficacy and safety of albumin-bound paclitaxel combined with anlotinib and immunotherapy in advanced non-small cell lung cancer with liver metastases: a retrospective study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo investigate the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) combined with anlotinib and immunotherapy as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC) and liver metastases.
methodsThis single-center, retrospective study enrolled patients with advanced NSCLC and liver metastases who experienced disease progression after first-line first‑line chemoimmunotherapy and subsequently received second-line treatment with nab-paclitaxel plus anlotinib and a PD-1/PD-L1 inhibitor between January 2021 and April 2024. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).
resultsA total of 32 patients were included in the analysis. The combination regimen demonstrated notable antitumor activity, with an ORR of 25.00% (8/32) and a DCR of 53.13% (17/32). The median PFS was 4.0 months (95% CI: 4.05–4.64), and the median OS was 9.0 months (95% CI: 8.38–9.49). Subgroup analysis indicated that patients who experienced treatment-related AEs such as hypertension, proteinuria, or hand-foot syndrome achieved better therapeutic outcomes than those who did not. Exploratory biomarker analysis suggested that the regimen may exert synergistic antitumor effects by modulating immune cell profiles and alleviating immunosuppression. The safety profile was generally manageable, with most AEs being mild to moderate in severity, indicating favorable tolerability.
conclusionThe combination of nab-paclitaxel, anlotinib, and immunotherapy appears to be a feasible and effective second-line treatment option for advanced NSCLC patients with liver metastases, offering comparable efficacy with acceptable toxicity. These findings warrant validation in prospective, randomized controlled trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.